Reviews evidence-based framework for managing weight regain after bariatric surgery, incorporating GLP-1 RAs as pharmacological adjuncts. Addresses the reality that up to 37% of bariatric surgery patients experience significant weight regain, with recurrence of comorbidities. Positions semaglutide and tirzepatide as second-line pharmacological options after surgical weight regain—providing clinical guidance for integrating pharmacotherapy with post-bariatric behavioral and nutritional interventions to achieve durable weight maintenance.
Niedbala, Christine G